Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis

Eric Nuermberger, Tetsuyuki Yoshimatsu, Sandeep Tyagi, Richard J. O'Brien, Andrew N. Vernon, Richard E Chaisson, William Ramses Bishai, Jacques H. Grosset

Research output: Contribution to journalArticle

Abstract

Tuberculosis continues to be a major cause of morbidity and mortality in the world. The expansion of tuberculosis control programs has been limited by the lengthy and cumbersome nature of current chemotherapeutic regimens. A new drug that improves the sterilizing activity of current regimens would reduce the duration of therapy without sacrificing efficacy, thereby enhancing treatment completion rates and preserving precious public health resources. The new 8-methoxyfluoroquinolone moxifloxacin has potent activity against both actively multiplying and nonactively multiplying tubercle bacilli. Using a murine model that is representative of chemotherapy for human tuberculosis, we show that the combination of moxifloxacin, rifampin, and pyrazinamide reduced the time needed to eradicate Mycobacterium tuberculosis from the lungs of infected mice by up to 2 months when compared with the standard regimen of isoniazid, rifampin, and pyrazinamide. The findings suggest that this regimen has the potential to substantially shorten the duration of therapy needed to cure human tuberculosis.

Original languageEnglish (US)
Pages (from-to)421-426
Number of pages6
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume169
Issue number3
StatePublished - Feb 1 2004
Externally publishedYes

Fingerprint

Tuberculosis
Pyrazinamide
Rifampin
Health Resources
Isoniazid
Mycobacterium tuberculosis
Bacillus
Therapeutics
Public Health
Morbidity
Drug Therapy
Lung
Mortality
moxifloxacin
Pharmaceutical Preparations

Keywords

  • Fluoroquinolone
  • Mouse
  • Moxifloxacin
  • Treatment
  • Tuberculosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis. / Nuermberger, Eric; Yoshimatsu, Tetsuyuki; Tyagi, Sandeep; O'Brien, Richard J.; Vernon, Andrew N.; Chaisson, Richard E; Bishai, William Ramses; Grosset, Jacques H.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 169, No. 3, 01.02.2004, p. 421-426.

Research output: Contribution to journalArticle

Nuermberger, Eric ; Yoshimatsu, Tetsuyuki ; Tyagi, Sandeep ; O'Brien, Richard J. ; Vernon, Andrew N. ; Chaisson, Richard E ; Bishai, William Ramses ; Grosset, Jacques H. / Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis. In: American Journal of Respiratory and Critical Care Medicine. 2004 ; Vol. 169, No. 3. pp. 421-426.
@article{cfced4db41ac40dba694d2a45afeb3bb,
title = "Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis",
abstract = "Tuberculosis continues to be a major cause of morbidity and mortality in the world. The expansion of tuberculosis control programs has been limited by the lengthy and cumbersome nature of current chemotherapeutic regimens. A new drug that improves the sterilizing activity of current regimens would reduce the duration of therapy without sacrificing efficacy, thereby enhancing treatment completion rates and preserving precious public health resources. The new 8-methoxyfluoroquinolone moxifloxacin has potent activity against both actively multiplying and nonactively multiplying tubercle bacilli. Using a murine model that is representative of chemotherapy for human tuberculosis, we show that the combination of moxifloxacin, rifampin, and pyrazinamide reduced the time needed to eradicate Mycobacterium tuberculosis from the lungs of infected mice by up to 2 months when compared with the standard regimen of isoniazid, rifampin, and pyrazinamide. The findings suggest that this regimen has the potential to substantially shorten the duration of therapy needed to cure human tuberculosis.",
keywords = "Fluoroquinolone, Mouse, Moxifloxacin, Treatment, Tuberculosis",
author = "Eric Nuermberger and Tetsuyuki Yoshimatsu and Sandeep Tyagi and O'Brien, {Richard J.} and Vernon, {Andrew N.} and Chaisson, {Richard E} and Bishai, {William Ramses} and Grosset, {Jacques H.}",
year = "2004",
month = "2",
day = "1",
language = "English (US)",
volume = "169",
pages = "421--426",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "3",

}

TY - JOUR

T1 - Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis

AU - Nuermberger, Eric

AU - Yoshimatsu, Tetsuyuki

AU - Tyagi, Sandeep

AU - O'Brien, Richard J.

AU - Vernon, Andrew N.

AU - Chaisson, Richard E

AU - Bishai, William Ramses

AU - Grosset, Jacques H.

PY - 2004/2/1

Y1 - 2004/2/1

N2 - Tuberculosis continues to be a major cause of morbidity and mortality in the world. The expansion of tuberculosis control programs has been limited by the lengthy and cumbersome nature of current chemotherapeutic regimens. A new drug that improves the sterilizing activity of current regimens would reduce the duration of therapy without sacrificing efficacy, thereby enhancing treatment completion rates and preserving precious public health resources. The new 8-methoxyfluoroquinolone moxifloxacin has potent activity against both actively multiplying and nonactively multiplying tubercle bacilli. Using a murine model that is representative of chemotherapy for human tuberculosis, we show that the combination of moxifloxacin, rifampin, and pyrazinamide reduced the time needed to eradicate Mycobacterium tuberculosis from the lungs of infected mice by up to 2 months when compared with the standard regimen of isoniazid, rifampin, and pyrazinamide. The findings suggest that this regimen has the potential to substantially shorten the duration of therapy needed to cure human tuberculosis.

AB - Tuberculosis continues to be a major cause of morbidity and mortality in the world. The expansion of tuberculosis control programs has been limited by the lengthy and cumbersome nature of current chemotherapeutic regimens. A new drug that improves the sterilizing activity of current regimens would reduce the duration of therapy without sacrificing efficacy, thereby enhancing treatment completion rates and preserving precious public health resources. The new 8-methoxyfluoroquinolone moxifloxacin has potent activity against both actively multiplying and nonactively multiplying tubercle bacilli. Using a murine model that is representative of chemotherapy for human tuberculosis, we show that the combination of moxifloxacin, rifampin, and pyrazinamide reduced the time needed to eradicate Mycobacterium tuberculosis from the lungs of infected mice by up to 2 months when compared with the standard regimen of isoniazid, rifampin, and pyrazinamide. The findings suggest that this regimen has the potential to substantially shorten the duration of therapy needed to cure human tuberculosis.

KW - Fluoroquinolone

KW - Mouse

KW - Moxifloxacin

KW - Treatment

KW - Tuberculosis

UR - http://www.scopus.com/inward/record.url?scp=1642537638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642537638&partnerID=8YFLogxK

M3 - Article

C2 - 14578218

AN - SCOPUS:1642537638

VL - 169

SP - 421

EP - 426

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 3

ER -